Your Immune System Is Overreacting. Your Genes May Be Why.

TNF-alpha is one of your immune system’s most powerful inflammatory signals. When your body detects a threat, immune cells release TNF-alpha to coordinate the attack. It increases blood flow to the affected area, activates immune cells, and tells your body this is an emergency. Once the threat is cleared, TNF-alpha levels should drop. Your body should return to baseline.

Here’s the problem: the TNF -308G>A variant, carried by roughly 30% of people with European ancestry, increases how much TNF-alpha your immune cells produce, even at baseline. People with the A allele tend to have elevated TNF-alpha even when there’s no active infection. That’s like having your alarm system set to “hair trigger” all the time. It creates a state of chronic low-grade systemic inflammation that wears on your joints, your gut lining, your nervous system.

You feel it as persistent joint stiffness that doesn’t match the activity you did. Low-grade fevers that come and go. Gut inflammation that makes you react to foods you used to tolerate. Brain fog that doesn’t lift with sleep. Your inflammatory baseline is just higher than it should be, so even minor stressors push you into symptomatic territory.

IL-6 is your immune system’s amplifier. When TNF-alpha or other signals activate your immune response, IL-6 turns up the volume. It signals your body to produce more inflammatory molecules, recruits more immune cells to the area, and extends the duration of the inflammatory response. This is useful when you’re fighting an actual infection. IL-6 is supposed to be short-lived and proportional to the threat.

The IL6 -174G>C variant, present in roughly 40% of the population, increases your baseline IL-6 production and your ability to amplify inflammatory response. People with the C allele tend to have higher resting IL-6 levels and mount bigger inflammatory reactions to stressors. This doesn’t just affect your joints or your gut. IL-6 crosses the blood-brain barrier readily. Elevated IL-6 drives neuroinflammation, contributing to brain fog, depression, and cognitive decline.

You might notice you get sick less often than average, which feels like an advantage, but when you do get sick, the symptoms are severe. You recover slowly. You feel fatigued for weeks after a minor infection. You have brain fog that feels like it’s independent of sleep or stress. Your inflammation response is dialed to eleven, and it doesn’t know how to dial back down.

Your HLA genes are your immune system’s identification system. They sit on the surface of your cells and display fragments of proteins to your immune system, essentially saying, “This is me, don’t attack.” When your immune system sees a fragment that looks foreign, it mounts an attack. The problem arises when something in the environment looks enough like your own cells that your immune system can’t tell the difference. This is the mechanism of autoimmune disease.

HLA-DQ2, present in roughly 25-30% of people with European ancestry, is required for celiac disease susceptibility. If you carry HLA-DQ2, your immune system can recognize gluten as a threat. But HLA-DQ2 also associates with type 1 diabetes, Hashimoto’s thyroiditis, and other autoimmune conditions. It’s not that everyone with HLA-DQ2 develops autoimmune disease. It’s that without HLA-DQ2, celiac disease is essentially impossible. With it, you have genetic risk that depends on environmental triggers.

You might have digestive symptoms that started in childhood or after a viral infection. Bloating, nutrient malabsorption, fatigue that doesn’t respond to iron supplementation. If you carry HLA-DQ2, gluten is not just uncomfortable; it’s triggering a cellular immune attack on your intestinal lining. The inflammation extends beyond your gut. Unaddressed, HLA-DQ2-related autoimmunity drives systemic inflammation that affects your joints, your thyroid, your brain.

CTLA4 is your immune system’s off switch for T-cells. T-cells are the soldiers of your immune system. They patrol your body looking for threats. But they need supervision. When a T-cell encounters something that looks dangerous, it wants to attack. CTLA4 is the checkpoint that says, “Wait, is this actually a threat, or is this something we’re supposed to tolerate?” It keeps T-cells from becoming overactive and attacking things they shouldn’t. This is especially important for preventing autoimmune disease.

The CTLA4 +49A>G variant, present in roughly 45% of the population, reduces how effectively CTLA4 can suppress T-cell activation. People with the G allele have T-cells that stay more active and attack-ready. They’re faster to respond to genuine threats, but they’re also more likely to make mistakes and attack your own cells. This variant significantly increases autoimmune disease risk across multiple conditions. Celiac disease, type 1 diabetes, rheumatoid arthritis, lupus, Hashimoto’s. The list is long.

You might notice you’re prone to multiple autoimmune conditions, or your autoimmune symptoms are more severe than average. You might have a strong family history of autoimmunity. Your immune system is fundamentally less good at distinguishing self from non-self. Infections trigger prolonged immune responses. Stress, which increases inflammatory signaling in everyone, has an outsized effect on your immune system.

PTPN22 is a brake on immune activation. It sits inside T-cells and B-cells and tells them when to stop attacking. It’s especially important in the early stages of immune response, preventing your immune system from overreacting to minor threats. When PTPN22 functions properly, your immune response is calibrated and proportional. When it doesn’t, your immune cells attack with less restraint.

The PTPN22 1858C>T variant, present in roughly 15-25% of European ancestry populations, impairs PTPN22’s ability to suppress immune activation, directly increasing autoimmune disease risk across multiple conditions. This variant associates with type 1 diabetes, rheumatoid arthritis, lupus, Graves’ disease, and many others. Having the T allele doesn’t mean you’ll develop autoimmune disease, but it significantly increases the probability. If you also carry CTLA4 variants or HLA-DQ2, the risk multiplies.

You might have a strong autoimmune disease family history. You might develop multiple autoimmune conditions simultaneously or in succession. Your immune system struggles with the basic distinction between foreign invaders and your own cells. Seemingly minor infections trigger disproportionate immune responses. You take longer to recover from illness than peers, and the recovery comes with lingering inflammation.

IRF5 is a master regulator of your immune system’s interferon response. Interferons are your immune system’s antiviral weapons. When a virus invades, infected cells release interferons to warn neighboring cells and activate antiviral defenses. This is essential for fighting viral infections. But interferon signaling is also tightly connected to autoimmune disease. Overactive interferon responses drive lupus and other systemic autoimmune conditions. Your immune system essentially treats your own tissues as if they’re infected.

IRF5 variants, particularly in the regulatory region, increase how readily your immune system mounts an interferon response to immune triggers. People with IRF5 variants have exaggerated interferon signaling, both to genuine viral threats and to the kinds of molecular patterns that might arise from tissue damage, stress, or even food proteins. This amplified interferon response drives systemic inflammation and significantly increases lupus and other autoimmune disease risk. The effect is gene-dose dependent; two copies of the variant confers higher risk than one copy.

You might have photosensitivity or unusual reactivity to sunlight. You get sick with viral infections frequently, but the infections linger and the recovery is prolonged. You have systemic symptoms that suggest autoimmune disease: joint pain, rashes, low-grade fevers, fatigue that doesn’t match activity level. If you’re female, risk is higher due to hormonal amplification of interferon responses.